RE
BHVN

RBC Europe’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

RBC Europe’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$2.58K – 1204
2018
Q1 		$2.58K Buy
+100
New +$2.99K ﹤0.01% 1032

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RBC Europe's BHVN Position: Q2 2018 in Review

RBC Europe sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2018, closing a stake of 100 shares — an estimated $2.58K sold.

RBC Europe first reported a position in BHVN in Q1 2018 and held it in 1 quarter. The position peaked at $2.58K in Q1 2018. 102 funds tracked by Wall St. Rank hold BHVN as of Q2 2018.

  • RBC Europe reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2018 after selling out during the quarter.
  • RBC Europe sold 100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2018, an estimated $2.58K.
  • RBC Europe first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 1 quarter.
  • RBC Europe's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.58K in Q1 2018.
  • 102 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2018.

Based on RBC Europe's 13F filing for Q2 2018, filed 9 Nov 2023.